Uterine Fundus Pressure in Reduction of Cesarean Bleeding
NCT ID: NCT06005831
Last Updated: 2023-08-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
482 participants
INTERVENTIONAL
2021-01-01
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Impact of Mechanical Methods on the Postpartum Haemorrhage Prophylaxis During Caesarean Section
NCT05948436
A Novel Technique Of Uterine Cooling During Repeated Cesarean Section For Reducing Blood Loss
NCT03793153
Extra-abdominal Removal of Placenta During CS
NCT02101450
The Effect of Abdominal Binder Use on Postpartum Pain, Bleeding, and Breastfeeding Success in Cesarean Delivery Women
NCT04965779
The Comparison of the Effect of Different Oxytocin Administrations on the Blood Loss During Cesarean Delivery
NCT03967171
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The standard sandbag used in our clinic was 20 × 20 × 3 cm3 in dimensions and 3 kg in weight. Sandbags of the same standard were used for all patients. After the patient was taken to the patient's bed, the uterine fundus was palpated, and then the sandbag was placed on the abdomen, just above the fundus, in such a way as to apply pressure to the fundus. The sandbag was kept on the abdomen for approximately 6 hours. During this period, the patient was followed up frequently and care was taken not to change the position of the sandbag. Sandbags were removed just before our patients were mobilized (approximately 6 hours). The sandbag was placed on the same spot in each patient by the obstetric assistants in our author team. In addition, preoperative and postoperative follow-ups and data acquisition and storage were performed by the same team 2.1 Study Design
It is a prospective, randomized, controlled single-center study.
2.2 Inclusion Criteria
All cases with CS who had a live pregnancy after 24 weeks of gestation were included in the study.
2.3 Exclusion Criteria
* Invasion anomaly,
* Diagnosed with preeclampsia,
* Placenta previa cases,
* Hypertensive pregnant women receiving antihypertensive therapy,
* Diabetic pregnant women,
* Multiple pregnancies,
* Major hepatic, cardiac, renal, respiratory disorders
* Deep vein thrombosis during pregnancy,
* Receiving anticoagulant therapy
* Patients who developed atony and uterine rupture in the operating room,
* Suspected placental invasion
* Uterine balloon tamponade
* Arterial embolization
* Uterine and hypogastric artery ligation,
* Uterine compression sutures
* Intraoperative blood loss was estimated to be over 1000 mL during CS and who received intraoperative blood transfusion
2.4 Patient Selection
For randomization, patients were fully informed about the study while preparing for CS. Sandbags were placed in all cases included in the study after meeting the study criteria for between 1 January 2021 and 30 June 2021. Sandbags were not placed in the cases who met the study criteria and were included in the study between 1 July 2021 and 31 December 2021.2.5 Sampling Technique
Qualified participants who gave informed consent to participate in the study were randomly assigned to groups. Visual analog scale (VAS) was used for postoperative pain scoring at the 8th and 24th postoperative hours. The patient included in the study was randomized into control group or weighted group by another assistant doctor who did not participate in the CS and did not know about the patient.
2.6 Postoperative Monitoring
All cases were given 10 IU of oxytocin IV during CS, after prophylactic antibiotic therapy and placenta separation. After CS, 40 IU of oxytocin (Synpitan® forte ampule 5 IU, Deva, Istanbul, Turkey) was administered intravenously in 500 mL saline and at an infusion rate of 125 mL/hour. At the same time, 0.2-0.4 µg methylergonovine maleate (Methergine® ampule 0.2 µmg, Sandoz, Istanbul, Turkey) was given intravenously/intramuscularly in cases without hypertension. All patients were treated according to the postoperative protocol for CS performed in our obstetrics clinic. At the 8th and 24th hours postoperatively, the researchers determined the patient's hemoglobin (Hb) and hematocrit (Hct) concentrations and the amount of vaginal bleeding. In addition, the time of milk coming from the breast and VAS were performed. Patients with a postoperative Hb value of \<7 g/dL received blood transfusion. Considering the risks of blood transfusion, blood transfusion is primarily planned in symptomatic patients with an Hct value of \<20%, as stated in the bulletin of The American College of Obstetricians and Gynecologists (ACOG), but if the Hb is below 7 g/dL, it is hemodynamically stable and in asymptomatic patients, the treatment is individualized and alternative to transfusion, oral anti anemic or intravenous iron therapy is applied.
2.7 Determination of the Amount of Postoperative Blood Loss
Postoperative blood loss was determined by monitoring the pad and measuring the hemoglobin values at the 8th and 24th hours in all cases. Standard pads measuring 10 × 10 cm2 was used. The main advantage of this method of visually assessing blood loss is that it is a real-time assessment and allows the person accompanying the delivery to correlate it with the patient's clinical findings. However, significant differences between clinical evaluation and actual measurements have been clearly demonstrated in many studies has been reported that gravimetric blood loss estimation methods or serum lactate measurements can provide a more objective assessment of bleeding. It has been reported that visual and gravimetric blood loss estimation measurements show a high degree of bias and therefore their routine use cannot be recommended. On the other hand, it has been stated that colorimetric technology offers real-time measurement and has a high degree of correlation. For this reason, we used the preoperatively and postoperatively at the 8th and 24th hours hemoglobin values. Postpartum anemia was defined as hemoglobin concentration (Hb) \<10 g/dL in the postpartum period.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sandbag
Sandbag
sandbag
The standard sandbag used in our clinic, 20 × 20 × 3 cm3 in dimensions and 3 kg in weight
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sandbag
The standard sandbag used in our clinic, 20 × 20 × 3 cm3 in dimensions and 3 kg in weight
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Diagnosed with preeclampsia,
* Placenta previa cases,
* Hypertensive pregnant women receiving antihypertensive therapy,
* Diabetic pregnant women,
* Multiple pregnancies,
* Major hepatic, cardiac, renal, respiratory disorders
* Deep vein thrombosis during pregnancy,
* Receiving anticoagulant therapy
* Patients who developed atony and uterine rupture in the operating room,
* Suspected placental invasion
* Uterine balloon tamponade
* Arterial embolization
* Uterine and hypogastric artery ligation,
* Uterine compression sutures
* Intraoperative blood loss was estimated to be over 1000 mL during CS and who received intraoperative blood transfusion
18 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Firat University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mustafa YILMAZ
Firat University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sehmus Pala
Role: STUDY_CHAIR
University of Firat
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Firat University Faculty of Medicine
Elâzığ, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020/14-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.